Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Firefighter™ PTCA Balloon Catheter Obtains Approval for Registration in Mexico


Mexico City, Mexico - On July 30, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") received the approval for registration of the independently developed Firefighter™ PTCA Balloon Catheter ("Firefighter™") in Mexico from the Mexican authority of COFEPRIS on top of the CE certification and CFDA registration approval. It has also been granted marketing certificates in Brazil, Argentina, Korea and India successively.
Firefighter™ is a rapid exchange PTCA Balloon Catheter, which can be used for the dilatation of coronary artery stenosis lesions to improve myocardial perfusion, and for the pre-dilatation of the lesions prior to the implantation of stents. It can be used in combination with Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), which was also independently developed by MicroPort®. Firefighter™ has relatively lower profile than that of its competitors of the same size, and is made of flexible materials, enabling the product to cross stenosis and tortuous lesions multiple times. Its design size allows the 5F guiding catheter to accommodate two Firefighter™ balloon catheters, so as to facilitate the complex techniques such as kissing balloon inflation. A total of 43 sizes with 12 diameters (1.0mm-4.0mm) and four lengths (6mm, 10mm, 15mm and 20mm) are covered by the registration approval for Firefighter™ in Mexico.
Previously, MicroPort® had gained the registration approvals for Firehawk®, Firebird2® Rapamycin-Eluting Coronary CoCr Stent System, FOXTROT™ PRO PTCA Balloon Catheter and FOXTROT™ NC PTCA Balloon Catheter in Mexico. MicroPort® International Business First Vice-President Dr. Linda Yingqing Lin said, "The registration approval for Firefighter™ has further widened the product line of MicroPort® in Mexico, tremendously driving the consolidation and growth of the market share of the company’s cardiovascular products in South America. In future, MicroPort® will commit itself to introduce more high-end medical device products of good quality and high affordability to the local market, so as to benefit more patients."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957


[Prev]:MicroPort® CRM Announces Change in Strategic Direction for Japan CRM Market and End of Distribution Agreement with JLL in One Year's Time
[Next]:Firehawk® Presented at the 15th Malaysian Cardiovascular Interventional Symposium with Live Transmission (MYLIVE2018)